Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Ventricular Tachycardia Devices Market $16.2 Billion by 2027

The global market for ventricular tachycardia devices estimated to reach $16.2 billion by 2027, growing at a CAGR of 6.1% over the forecast period, driven by increasing prevalence of ischemic heart disease or coronary artery disease, higher preference for less-invasive and preventive interventional treatments, and recent technological developments.

Global Ventricular Tachycardia Devices Market

Ventricular tachycardia (V-tach or VT) is a heart rhythm disorder (arrhythmia) caused by abnormal electrical signals in the lower chambers of the heart (ventricles). Ventricular tachycardia is characterized as a wide complex tachyarrhythmia. Ventricular tachycardia is commonly seen in medical practice.

  • Ventricular tachycardia is caused by a disruption in the normal electrical impulses that control the rate of heart’s pumping action. Ventricular tachycardia accounts for approximately 8% of cases of wide complex tachycardia. The most common cause of ventricular tachycardia is underlying ischemic heart disease (IHD).
    • Other causes include adult and congenital structural heart disease, acquired and inherited channelopathies, infiltrative cardiomyopathy, electrolyte imbalances (hypokalemia, hypocalcemia, hypomagnesemia), illicit drugs such as cocaine or methamphetamine, and digitalis toxicity.
      • Ventricular arrhythmias are a significant cause of morbidity and mortality in patients with ischemic structural heart disease.
  • The prevalence of ventricular arrhythmia is approximately 69,000 per 100,000 men and 68,000 per 10,00,000 women with coronary artery disease worldwide.
    • The prevalence of ventricular tachycardia is approximately 54,000 per 100,000 in men and 55,000 per 100,000 in women with hypertension, valvular heart disease, or cardiomyopathy without coronary artery disease and 31,000 per 100,000 in men and 30,000 per 100,000 in women with no cardiovascular disease.

The prognosis of VT depends on the cause and cardiac status. Various diagnostic criteria have been developed to determine whether a wide complex tachycardia is ventricular tachycardia or a more benign rhythm. It may be completely benign or portend high risk for sudden cardiac death. Ventricular tachycardia and ventricular fibrillation are the most important causes of sudden cardiac death (SCD), particularly in those with structural heart disease and reduced left ventricular function.

  • The best way to prevent ventricular tachycardia is to treat or eliminate risk factors that may lead to heart disease. Therapy may be directed either at terminating an episode of the abnormal heart rhythm or at reducing the risk of another VT episode.
    • The goals of ventricular tachycardia treatment include restoration of normal heart rhythm, controlling the fast heart rate when it occurs, and preventing future episodes of tachycardia. With treatment, it may be possible to prevent or manage episodes of ventricular tachycardia.

The specific treatment depends on the cause of arrhythmia and the type or severity of ventricular tachycardia. Sustained ventricular tachycardia often requires urgent medical treatment, as this condition may sometimes lead to sudden cardiac death. The first-line therapy for chronic treatment of patients with ischemic heart disease and VT is a beta-blocker therapy which is associated with a reduced risk of sudden cardiac death.

  • Treatment also involves restoring a normal heart rate by delivering a jolt of electricity to the heart. This may be done using a defibrillator or with a treatment called cardioversion. Treatment modalities include simple beta-blockade to implantation of implantable cardiac defibrillator and ablative approaches.
  • The ICD continuously monitors the heartbeat, detects an increase in heart rate and delivers precisely calibrated electrical shocks, if needed, to restore a normal heart rhythm.
    • An implantable ICD is more effective than drug therapy for prevention of sudden cardiac death due to VT and ventricular fibrillation (VF), but may be constrained by cost issues, as well as patient co-morbidities and patient preference.
  • Cardiac resynchronization defibrillator implantation reduces mortality and heart failure hospitalization for patients with functional class II or III heart failure and left bundle branch block in comparison to implantable defibrillator alone.
    • Cardiac resynchronization was found to significantly reduce new-onset and first recurrences of ventricular arrhythmias for patients who have not experienced prior ventricular arrhythmias. CRT reduced the rate of onset of new ventricular arrhythmias detected by ICDs in patients without a history of prior ventricular arrhythmias.
      • The influence of cardiac resynchronization therapy (CRT) on ventricular arrhythmias, however, is less certain. For patients with a history of ventricular arrhythmias, there was a statistically insignificant trend to increased ventricular arrhythmias with cardiac resynchronization pacing.
  • Catheter ablation procedure is often used when a discrete electrical pathway is responsible for an increased heart rate. Electrodes at the catheter tips can use extreme cold or radiofrequency energy to damage (ablate) the extra electrical pathway and prevent it from sending electrical signals. Catheter ablation is a possible treatment for those with recurrent VT.

The global market for ventricular tachycardia devices research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global market for ventricular tachycardia devices segmented by product [therapeutic cardiac rhythm management devices (implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillator), directed energy-based therapy devices (thermal ablation catheters and devices), and geography.

  • Based on the products, the implantable cardioverter defibrillators (ICDs) segment accounted for the largest share of the total ventricular tachycardia devices market, followed by the cardiac resynchronization therapy defibrillator (CRT-D) segment.
    • ICDs have been very useful in preventing sudden death in patients with known, sustained ventricular tachycardia or fibrillation. Studies have shown that they may have a role in preventing cardiac arrest in high-risk patients with life-threatening ventricular arrhythmias.
      • Newer-generation ICDs may have a dual function which includes the ability to serve as a pacemaker. The pacemaker feature would stimulate the heart to beat if the heart rate is detected to be too slow.
        • Implantable cardioverter-defibrillators are now widely used in patients who survive sustained VT or VF that is not attributable to a transient correctable cause, or who are at high risk for recurrent arrhythmia. ICDs are dramatically effective for terminating VT and VF.
  • However, the energy-based thermal ablation catheters and therapy devices segment anticipated to witness the fastest double-digit growth rate during the forecast period.
    • Catheter ablation is being increasingly performed as adjunctive treatment to prevent recurrent implantable cardioverter-defibrillator therapies in patients with nonischemic cardiomyopathy and ventricular tachycardia (VT).
      • In the context of VT ablation, nonischemic cardiomyopathy usually refers to dilated cardiomyopathy (DCM) as one morphological phenotype.
        • Data from the 2003 to 2014 National Inpatient Sample databases suggest an increasing trend in the use of VT ablation after the exclusion of patients with coronary artery disease.

The global market for ventricular tachycardia devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geographic distribution, the North America region dominated the global market, closely followed by Europe region. 
    • Ventricular tachycardia and ventricular fibrillation cause most cases of sudden cardiac death with an estimated rate of 300,000 deaths each year in the United States.
      • This accounts for approximately half of the deaths related to cardiac causes. VT is rare in children but can occur in the presence of structural heart disease. Overall, VT is more common in men than in women.
    • According to the European Heart Rhythm Association/Heart Failure Association, coronary artery disease (CAD) has been recognized to be the major cause of VT in Europe. There are at least 15 million patients with heart failure (HF) in Europe alone.
      • In patients with high risk for sudden cardiac death, an ICD is routinely implanted, while the treatments vary among the patients with moderate and low risk. New developments in cardiac monitoring, cardiac resynchronization therapy (CRT), and other implantable devices allow better detection and treatment of cardiac arrhythmias in HF, opening more opportunities for improvements in management.
  • On the other hand, the Asia Pacific and Rest of the World regions expected to register the fastest double-digit growth rate in the coming years.
    • Many low- and middle-income countries (LMICs) are undergoing an epidemiological transition. With an improvement in socioeconomic conditions and an aging population, cardiovascular diseases (CVDs), like cardiac arrhythmias, are expected to increase in these countries.
      • Although the prevalence is relatively lower in Asians than in Westerners, the prognostic impacts on stroke and mortality in Asians are comparable. Sudden cardiac death (SCD) occurs in approximately 40 cases per 100,000 persons annually in each country of Asia.
        • Most cases are caused by myocardial infarction and ventricular fibrillation in out-of-hospital cardiac arrest cases, but the proportion of myocardial infarction is lower in Asia than in Western countries.
          • Implantable cardioverter-defibrillator implantation has become established as an effective secondary prevention for SCD, and numbers have been increasing annually worldwide.

In addition, the market for ventricular tachycardia devices report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for ventricular tachycardia devices and profiled in this report include Abbott Laboratories, Inc. (St. Jude Medical, Inc.), Biotronik SE & Co. KG, Boston Scientific Corporation, EBR Systems, Inc., Johnson & Johnson (Biosense Webster, Inc.), LivaNova plc, Medtronic plc, Thermedical, Inc., and ZOLL Medical Corporation.

  • Product
    • Therapeutic Cardiac Rhythm Management Devices
      • Implantable Cardioverter Defibrillators (ICDs)
      • Cardiac Resynchronization Therapy Defibrillator (CRT-D)
    • Directed Energy-based Therapy Devices
      • Thermal Ablation Catheters and Devices
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc. (St. Jude Medical, Inc.)
    • Biotronik SE & Co. KG
    • Boston Scientific Corporation
    • EBR Systems, Inc.
    • Johnson & Johnson (Biosense Webster, Inc.)
    • LivaNova plc
    • Medtronic plc
    • Thermedical, Inc.
    • ZOLL Medical Corporation

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]eanalyst.com